Dr. Ian Miller

print version
'Dr. Ian Miller' image

After completing his PhD studies in 2008 in Biomedical science and Engineering at The Conway Institute (UCD) investigating the interaction of cancer cells and novel growth surfaces, Dr.Ian Miller completed a post-doctoral placement in the UCD school of Veterinary Medicine elucidating the transcription regulation of genes determining virulence using RNA seq technology in Leptospira interrogans and its interaction with the reservoir host to casue chronic but asymptomatic disease.

After this placement Dr. Miller travelled to the Feinstein Institute for Medical Research (NSLIJ Health System) New York to complete a Post-doctoral Fellowship determining factors of communication between microglia and the progression and development of glioblastoma multiforme (GBM). Primarily he focused on the enhancement of invasion of the glioma cells when in combination with microglia and the survival advantage the microglia bestowed on the glioma cells after therapeutic radiation. These studies led to discovery of a novel microglial modulating drug which enhanced the treatment of GBM when in combination with radiotherapy and standard chemotherapy. During this Fellowship Dr. Miller gained significant experience in tumour modelling and elucidation of cancer therapy mechanisms of action.

Dr. Miller is currently working as a Marie Curie Fellow at the Royal College of Surgeons in Ireland on the AngioTox project to interrogate angiogenesis inhibitor (AI) toxicities, implementing a state of the art molecular imaging approach. They will also seek to identify predictive safety and efficacy biomarkers for the AI class of agent.